. 2023 May 28;9(5):354–366. doi: 10.1002/cjp2.326

Table 3.

Clinicopathological characteristics related to epigenetic changes.

Degree of epigenetic change	N‐epi	S‐epi	D‐epi
Age ≧ 65 years	69.2% (9/13)	82.8% (24/29)^*	80.0% (20/25)
Male	30.8% (4/13)	44.8% (13/29)	48.0% (12/25)^*
Female	69.2% (9/13)	55.2% (16/29)	52.0% (13/25)
CA19‐9 ≧ 200 U/ml	15.4% (2/13)	35.5% (10/29) ^†	36.0% (9/25) ^†
Tumor size ≧ 30 mm	38.5% (5/13)	37.9% (11/29)	60.0% (15/25) ^† ^, ^‡
N1	46.2% (6/13)	51.7% (15/29)	68.0% (17/25) ^† ^, ^§
Borderline resectable	15.4% (2/13)	10.3% (3/29)	32.0% (8/25) ^† ^, ^‡
Poorly differentiated	7.7% (1/13)	20.7% (6/29)^*	52.0% (13/25) ^† ^, ^‡
v2‐3	69.2% (9/13)	72.4% (21/29)	96.0% (24/25) ^† ^, ^‡
ly2‐3	46.2% (6/13)	62.1% (18/29)^*	80.0% (20/25) ^† ^, ^‡
ne2‐3	84.6% (11/13)	89.7% (26/29)	100% (25/25) ^† ^, ^‡
E‐cadherin expression, low	30.8% (4/13)	55.2% (16/29) ^†	72.0% (18/25) ^† ^, ^§

D‐epi, subjects showing dual epigenetic change; N‐epi, subjects showing non‐epigenetic change; S‐epi, subjects showing single epigenetic change.

P < 0.05 versus N‐epi.

^{^†}

P < 0.01 versus N‐epi.

^{^‡}

P < 0.01 versus S‐epi.

^{^§}

P < 0.05 versus S‐epi.